25 completed, 12 terminated, 11 active not recruiting, 6 recruiting. 61 Phase 2, 7 Phase 1.
Follow Hypergammaglobulinemia: new trials by email Literature Review of Hypergammaglobulinemia trials Research Report on Hypergammaglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daratumumab for Polyneuropathy Associated With MGUS Daratumumab and hyaluronidase-fihj - Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance | Phase 2 | Withdrawn | Georgetown University | 2025-09-26 | 2025-10-01 | |
| Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma Isatuximab, Iberdomide, Dexamethasone - Smouldering Myeloma | Phase 2 | Recruiting | University College, London | 63 | 2025-06-02 | 2026-10-20 |
| A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma Linvoseltamab - Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 116 | 2024-09-16 | 2026-07-08 |
| Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma Elranatamab - Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | European Myeloma Network B.V. | 50 | 2024-05-14 | 2026-09-02 |
| Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy Zanubrutinib Oral Product - Monoclonal Gammopathy of Uncertain Significance | Phase 2 | Active not recruiting | UMC Utrecht | 35 | 2024-03-01 | 2026-05-08 |
| A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma Linvoseltamab - Smoldering Multiple Myeloma (SMM) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 40 | 2024-01-30 | 2026-04-13 |
| Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma Selinexor - Smoldering Multiple Myeloma | Phase 2 | Recruiting | University of Rochester | 15 | 2023-08-21 | 2025-02-10 |
| The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma TG01 - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Oslo University Hospital | 20 | 2023-05-19 | 2025-08-05 |
| CAR- PRISM (PRecision Intervention Smoldering Myeloma) Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2023-04-19 | 2026-03-12 |
| Immuno-PRISM (PRecision Intervention Smoldering Myeloma) Teclistamab, Lenalidomide, Dexamethasone - High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma | Phase 2 | Recruiting | Irene Ghobrial, MD | 52 | 2022-08-10 | 2026-07-16 |
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma Bone Marrow Biopsy, Dexamethasone, Lenalidomide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Terminated | Mayo Clinic | 17 | 2022-06-15 | 2026-09-28 |
| Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients Cholestyramine, Leflunomide - Smoldering Plasma Cell Myeloma | Phase 2 | Active not recruiting | City of Hope Medical Center | 27 | 2022-03-07 | 2026-04-30 |
| Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer Curcumin plus Piperine - Prostate Cancer, Multiple Myeloma | Phase 2 | Completed | University of Rochester | 30 | 2021-12-14 | 2026-05-12 |
| Isatuximab in Type I Cryoglobulinemia Isatuximab Injection - Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 21 | 2021-11-01 | 2021-11-09 |
| Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma Dexamethasone, Iberdomide Hydrochloride, Quality-of-Life Assessment - Smoldering Plasma Cell Myeloma | Phase 2 | Recruiting | Emory University | 68 | 2021-07-09 | 2026-06-01 |
| Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma Metformin XR, Placebo - Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 60 | 2021-04-27 | 2026-02-09 |
| Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia Ibrutinib, Daratumumab - Waldenstrom Macroglobulinemia, Waldenstrom's Disease | Phase 2 | Terminated | Weill Medical College of Cornell University | 1 | 2020-07-30 | 2023-10-23 |
| Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma Leflunomide, Quality-of-Life Assessment, Questionnaire Administration - Smoldering Plasma Cell Myeloma | Phase 2 | Withdrawn | City of Hope Medical Center | 2019-12-11 | 2019-11-14 | |
| Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA], Placebo 1.7 ml Subcutaneous Solution - Multiple Myeloma | Phase 2 | Completed | Arbeitsgemeinschaft medikamentoese Tumortherapie | 8 | 2019-09-30 | 2025-02-11 |
| A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) Carfilzomib, Lenalidomide, Dexamethasone - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 2 | Enrolling by invitation | Landspitali University Hospital | 80 | 2019-06-24 | 2019-08-16 |
Showing 20 of 61. Sign in to see all of them.
Smoldering Multiple Myeloma (44) · Multiple Myeloma (30) · Monoclonal Gammopathy of Undetermined Significance (23) · Neoplasms, Plasma Cell (17) · Precancerous Conditions (11) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Burkitt Lymphoma (9) · Leukemia (9) · Lymphoma, B-Cell, Marginal Zone (9) · Lymphoma, Follicular (9) · Lymphoma, Large B-Cell, Diffuse (9) · Lymphoma, Large-Cell, Immunoblastic (9) · Lymphoma, Mantle-Cell (9) · Lymphoma, Non-Hodgkin (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9)
Hemic and Lymphatic Diseases (61) · Blood Protein Disorders (60) · Hematologic Diseases (60) · Immune System Diseases (60) · Immunoproliferative Disorders (60) · Paraproteinemias (58) · Neoplasms (56) · Precancerous Conditions (43) · Neoplasms by Histologic Type (36) · Cardiovascular Diseases (32) · Hemorrhagic Disorders (32) · Hemostatic Disorders (32) · Vascular Diseases (32) · Lymphoproliferative Disorders (31)
Dexamethasone (12) · Lenalidomide (10) · Calcium Dobesilate (6) · daratumumab (5) · Cyclophosphamide (4) · Peripheral Blood Stem Cell Transplantation (4) · carfilzomib (4) · Bortezomib (3) · Melphalan (3) · fludarabine phosphate (3) · isatuximab (3) · Denosumab (2) · Epoetin Alfa (2) · Granulocyte Colony-Stimulating Factor (2) · Leflunomide (2)
Dana-Farber Cancer Institute (6) · National Cancer Institute (NCI) (4) · City of Hope Medical Center (3) · Mayo Clinic (3) · University of Rochester (3) · Novartis Pharmaceuticals (2) · Regeneron Pharmaceuticals (2) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Assistance Publique - Hôpitaux de Paris (1) · Barbara Ann Karmanos Cancer Institute (1) · BioInvent International AB (1) · Bristol-Myers Squibb (1) · Cancer Treatment Centers of America (1) · Case Comprehensive Cancer Center (1) · Emory University (1)
United States (45) · France (5) · Germany (4) · Italy (4) · Netherlands (4) · Spain (4) · Norway (3) · United Kingdom (3) · Belgium (2) · Czechia (2) · Israel (2) · Turkey (Türkiye) (2) · Australia (1) · Austria (1) · Canada (1)
Irene Ghobrial, MD (3) · Brea Lipe (2) · A. Broijl (1) · Ajai Chari, MD (1) · Amitabha Mazumder, MD (1) · Antonio T. Fojo, MD, PhD (1) · Benn E. Smith, MD (1) · Brian Durie, MD (1) · Carl O Landgren, M.D. (1) · Catherine R Marinac, PhD (1) · Charles L. Loprinzi, M.D. (1) · Choon-Kee Lee, MD (1)
PMID 19170225, PMID 19841031, PMID 20307284, PMID 24045500, PMID 24658821, PMID 26690712, PMID 28158311, PMID 28482144, PMID 32024950, PMID 33474705, PMID 38652812, PMID 38699307, PMID 38988266, PMID 39038268, PMID 39652826, PMID 39753553, PMID 42010117, PMID 42728379
2023 (2), 2009 (1), 2014 (1), 2017 (1), 2018 (1), K22CA251648 (1), P30CA015083 (1), P30CA016058 (1), P30CA022453 (1), P30CA033572 (1), P30CA043703 (1), P30CA138292 (1), UL1RR024150 (1)